ASCEND SCIENCE
Christmas Came EarlyAll Season Long
Buy 1, Get 1 Free Sitewide · Code:BOGO

ARA-290

Size: 10mg

ARA-290
$75.00$37.50per vial

With code BOGO

ARA-290 (cibinetide) is an 11–amino acid peptide modeled on the tissue-protective region of erythropoietin, studied for anti-inflammatory and tissue-repair signaling without stimulating red blood cell production.

ARA-290 (Cibinetide)

  • 11-amino-acid peptide based on the helix-B surface region of erythropoietin (EPO)

    Non-hematopoietic — does not raise red blood cell counts

  • Selectively activates the innate repair receptor (EPOR / CD131 heterodimer)

    Studied for anti-inflammatory and tissue-protective signaling

  • Referenced in neuropathic-pain and small-fiber-neuropathy research models

Research Use Notes

  • Supplied as lyophilized powder

    Requires reconstitution before use

  • Research Water required for mixing (sold separately)

    Swirl gently, never shake

Storage

  • Store lyophilized vial frozen for long-term holding

  • Keep reconstituted solution at 2 to 8°C

    Protect from light and heat

Handling

  • Maintain sterile technique throughout reconstitution

    For laboratory research use only

  • Avoid repeated freeze-thaw cycles to preserve integrity

Certificate of Analysis

Independently 8x Tested by Kovera Labs and/or ILS Labs

(Click here to learn about 8x testing)

LatestISO 170258× Testing
99.90%
Purity
Passed full QC panel
Variant
ARA-290 10 mg
Lot #
AS-ARA10-3
Labeled
10 mg
Actual
10.54mg
Tested
Sep 24, 2026
Full QC Panel8× tested
  • Purity (HPLC)99.90%
  • Net Peptide Content10.54mg
  • Identity (LC-MS)ARA-290
  • HPLC Conformitymean 99.90%
  • Heavy Metals (ICP-MS)Not Detected
  • Sterility (PCR)No Growth
  • Endotoxin (USP <85>)0.213 EU/mL
  • Fentanyl ScreenNot Detected
ISO/IEC 17025 Accredited

All certificates are issued by independent ISO-accredited laboratories. Lot-specific documents are made available to qualified research professionals on request.

Frequently Bought Together

Commonly paired to support consistent, reliable experimentation.

BPC-157

BPC-157

$75$37.50per vialWith code BOGO

Tissue Repair Peptide

KPV

KPV

$70$35per vialWith code BOGO

Anti-Inflammatory Research Peptide

MOTS-c

MOTS-c

From$70$35per vialWith code BOGO

Mitochondrial Research Peptide

Select Size

TB-500

TB-500

$75$37.50per vialWith code BOGO

Tissue Repair Peptide

GLP-3 RT

GLP-3 RT

From$65$32.50per vialWith code BOGO

Metabolic Research Peptide

Select Size

Tesamorelin

Tesamorelin

From$60$30per vialWith code BOGO

Growth Hormone Peptide

Select Size

Adamax

Adamax

From$60$42With code ASCEND30

Nootropic Research Peptide

Select Size

NAD+

NAD+

From$75$37.50per vialWith code BOGO

Cellular Longevity Coenzyme

Select Size

Compound Information

Technical specifications

Molecular Profile

What Is ARA-290?

Cibinetide · Erythropoietin-derived peptide

Type
Synthetic peptide (EPO-derived)
CAS Number
1208243-50-8
Molecular Weight
1,257.4 g/mol
Amino Acids
11
PubChem Database
Storage Requirements

Stability Information

Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)

-20°C

24+ months

Reconstituted

2-8°C

~30 days

Sources & References

Peer-reviewed research

Molecular Medicine

ARA-290 (Cibinetide) and the Innate Repair Receptor in Neuropathy

Review

View SourcePubMed Central

ARA-290 in Small-Fiber Neuropathy and Sarcoidosis — Clinical Research

View SourcePubMed

Cibinetide, Tissue Protection and Inflammation Resolution

View SourcePubChem

ARA-290 Compound Information

View SourceClinicalTrials.gov

ARA-290 (Cibinetide) Clinical Trials Registry

View Source
For Research Use Only

Products are intended solely for laboratory and scientific research purposes. Not intended for human consumption, veterinary use, diagnosis, treatment, cure, or prevention of disease.

Ascend Science GLP-2 TZ research vialAscend Science GLP-3 RT research vial

All the research compounds you need, with the confidence that every batch is 8× tested before it ships.

See all products

Subscribe to our Newsletter

Subscribe to our newsletter to get daily insights, news, updates.